Nicolas A Bamat1, Timothy D Nelin2, Eric C Eichenwald3, Haresh Kirpalani3, Matthew M Laughon4, Wesley M Jackson4, Erik A Jensen3, Kathleen A Gibbs3, Scott A Lorch3. 1. Division of Neonatology and Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA. Electronic address: bamatn@email.chop.edu. 2. Pediatrics Residency Program, Children's Hospital of Philadelphia, Philadelphia, PA. 3. Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA. 4. Division of Neonatology, Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract
OBJECTIVES: To measure between-center variation in loop diuretic use in infants developing severe bronchopulmonary dysplasia (BPD) in US children's hospitals, and to compare mortality and age at discharge between infants from low-use centers and infants from high-use centers. STUDY DESIGN: We performed a retrospective cohort study of preterm infants at <32 weeks of gestational age with severe BPD. The primary outcome was cumulative loop diuretic use, defined as the proportion of days with exposure between admission and discharge. Infant characteristics associated with loop diuretic use at P < .10 were included in multivariable models to adjust for center differences in case mix. Hospitals were ranked from lowest to highest in adjusted use and dichotomized into low-use centers and high-use centers. We then compared mortality and postmenstrual age at discharge between the groups through multivariable analyses. RESULTS: We identified 3252 subjects from 43 centers. Significant variation between centers remained despite adjustment for infant characteristics, with use present in an adjusted mean range of 7.3% to 49.4% of days (P < .0001). Mortality did not differ significantly between the 2 groups (aOR, 0.98; 95% CI, 0.62-1.53; P = .92), nor did postmenstrual age at discharge (marginal mean, 47.3 weeks [95% CI, 46.8-47.9 weeks] in the low-use group vs 47.4 weeks [95% CI, 46.9-47.9 weeks] in the high-use group; P = .96). CONCLUSIONS: A marked variation in loop diuretic use for infants developing severe BPD exists among US children's hospitals, without an observed difference in mortality or age at discharge. More research is needed to provide evidence-based guidance for this common exposure.
OBJECTIVES: To measure between-center variation in loop diuretic use in infants developing severe bronchopulmonary dysplasia (BPD) in US children's hospitals, and to compare mortality and age at discharge between infants from low-use centers and infants from high-use centers. STUDY DESIGN: We performed a retrospective cohort study of preterm infants at <32 weeks of gestational age with severe BPD. The primary outcome was cumulative loop diuretic use, defined as the proportion of days with exposure between admission and discharge. Infant characteristics associated with loop diuretic use at P < .10 were included in multivariable models to adjust for center differences in case mix. Hospitals were ranked from lowest to highest in adjusted use and dichotomized into low-use centers and high-use centers. We then compared mortality and postmenstrual age at discharge between the groups through multivariable analyses. RESULTS: We identified 3252 subjects from 43 centers. Significant variation between centers remained despite adjustment for infant characteristics, with use present in an adjusted mean range of 7.3% to 49.4% of days (P < .0001). Mortality did not differ significantly between the 2 groups (aOR, 0.98; 95% CI, 0.62-1.53; P = .92), nor did postmenstrual age at discharge (marginal mean, 47.3 weeks [95% CI, 46.8-47.9 weeks] in the low-use group vs 47.4 weeks [95% CI, 46.9-47.9 weeks] in the high-use group; P = .96). CONCLUSIONS: A marked variation in loop diuretic use for infants developing severe BPD exists among US children's hospitals, without an observed difference in mortality or age at discharge. More research is needed to provide evidence-based guidance for this common exposure.
Authors: Veena S Rao; Noah Planavsky; Jennifer S Hanberg; Tariq Ahmad; Meredith A Brisco-Bacik; Francis P Wilson; Daniel Jacoby; Michael Chen; W H Wilson Tang; David Z I Cherney; David H Ellison; Jeffrey M Testani Journal: J Am Soc Nephrol Date: 2017-07-24 Impact factor: 10.121
Authors: Erik A Jensen; Ammie M White; Peihui Liu; Keolamau Yee; Brenda Waber; Heather M Monk; Huayan Zhang Journal: Am J Perinatol Date: 2015-08-21 Impact factor: 1.862
Authors: Erik A Jensen; Kevin Dysart; Marie G Gantz; Scott McDonald; Nicolas A Bamat; Martin Keszler; Haresh Kirpalani; Matthew M Laughon; Brenda B Poindexter; Andrea F Duncan; Bradley A Yoder; Eric C Eichenwald; Sara B DeMauro Journal: Am J Respir Crit Care Med Date: 2019-09-15 Impact factor: 21.405
Authors: Matthew M Laughon; Kim Chantala; Sofia Aliaga; Amy H Herring; Christoph P Hornik; Rachel Hughes; Reese H Clark; P Brian Smith Journal: Am J Perinatol Date: 2014-05-06 Impact factor: 3.079
Authors: Nicolas A Bamat; Elizabeth J Thompson; Rachel G Greenberg; Scott A Lorch; Athena F Zuppa; Eric C Eichenwald; Veeral N Tolia; Reese H Clark; P Brian Smith; Christoph P Hornik; Jason E Lang; Matthew M Laughon Journal: J Perinatol Date: 2022-01-24 Impact factor: 3.225